ProQR Therapeutics (PRQR) Cash & Equivalents (2021 - 2025)
Historic Cash & Equivalents for ProQR Therapeutics (PRQR) over the last 4 years, with Q4 2024 value amounting to $159.7 million.
- ProQR Therapeutics' Cash & Equivalents rose 2477.45% to $159.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $159.7 million, marking a year-over-year increase of 2477.45%. This contributed to the annual value of $161.7 million for FY2024, which is 2570.42% up from last year.
- According to the latest figures from Q4 2024, ProQR Therapeutics' Cash & Equivalents is $159.7 million, which was up 2477.45% from $128.0 million recorded in Q4 2023.
- ProQR Therapeutics' Cash & Equivalents' 5-year high stood at $214.5 million during Q4 2021, with a 5-year trough of $91.3 million in Q2 2021.
- In the last 4 years, ProQR Therapeutics' Cash & Equivalents had a median value of $140.0 million in 2023 and averaged $144.5 million.
- Over the last 5 years, ProQR Therapeutics' Cash & Equivalents had its largest YoY gain of 13007.06% in 2022, and its largest YoY loss of 5492.59% in 2022.
- ProQR Therapeutics' Cash & Equivalents (Quarter) stood at $214.5 million in 2021, then plummeted by 54.93% to $96.7 million in 2022, then surged by 32.33% to $128.0 million in 2023, then increased by 24.77% to $159.7 million in 2024.
- Its Cash & Equivalents was $159.7 million in Q4 2024, compared to $128.0 million in Q4 2023 and $131.2 million in Q3 2023.